Proactively manage your pharmacy inventory
Anticipate generic drug launch
Manage your formulary budget
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Human lysosomal proteins from plant cell culture|
|Abstract:||A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.|
|Inventor(s):||Shaaltiel; Yoseph (Doar-Na Galil Elyon, IL), Baum; Gideon (D.N. Upper Galilee, IL), Bartfeld; Daniel (Kiryat Shmona, IL), Hashmueli; Sharon (Yesod-HaMaala, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)|
|Assignee:||Protalix Ltd. (Carmiel, IL)|
|Filing Date:||Apr 30, 2007|
|Claims:||1. An isolated nucleic acid sequence encoding a human glucocerebrosidase protein having an amino acid sequence as set forth in SEQ ID NO: 15. |
2. The isolated nucleic acid of claim 1, wherein said nucleic acid sequence is as set forth in SEQ ID NO: 13.
3. A nucleic acid construct capable of expression in a plant cell comprising the isolated nucleic acid of claim 1.
4. An isolated cell comprising the nucleic acid construct of claim 3.
5. The cell of claim 4, recombinantly producing said human glucocerebrosidase.
6. The cell of claim 4, wherein said human lysosomal protein is recombinantly produced so as to have at least one xylose and at least one exposed mannose residue.
7. The cell of claim 4, wherein said human lysosomal protein is recombinantly produced so as to have at least one core .alpha.-(1,2) xylose and at least one core .alpha.-(1,3) fucose.
8. The cell of claim 4, wherein said cell is a plant cell.
9. The cell of claim 8, wherein said plant cell is a plant root cell selected from the group consisting of Agrobacterium rihzogenes transformed root cell, celery cell, ginger cell, horseradish cell and carrot cell.
10. The cell of claim 9, wherein said plant cell is a carrot cell.
11. A method of producing a recombinant human glucocerebrosidase protein comprising: preparing a culture of recombinant cells transformed or transfected with the nucleic acid construct of claim 3; and culturing said cell culture under conditions permitting the expression of said protein, wherein said cells produce said glucocerebrosidase protein having an amino acid sequence as set forth in SEQ ID NO: 15 and at least one xylose residue.
12. The method of claim 11, wherein said cell culture is cultured in suspension.
13. The method of claim 11, further comprising: purifying said protein.
14. The method according to claim 11, wherein said cell is as defined by claim 6.
15. The method according to claim 11, wherein said lysosomal protein binds to a mannose receptor on a macrophage.
16. The method according to claim 15, wherein said lysosomal protein has increased affinity for said macrophage, in comparison with the corresponding affinity of a naturally occurring lysosomal protein to said macrophage.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.